***PKTX..We Have PR News.. :+O ProtoKinetix AA
Post# of 88
(Total Views: 319)
Posted On: 09/04/2018 10:17:19 AM
***PKTX..We Have PR News.. :+O
ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care SolutionsPress Release | 09/04/2018
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix"
(OTCQB
KTX)
...President and Chief Executive Officer Clarence Smith is pleased at the progress of the health care applications projects the Company has underway. According to Mr. Smith “To that end, ProtoKinetix is continuing to collaborate with some of the most prestigious research institutions.
..The Company is focusing on research efforts in areas where our AAGP® molecule can significantly impact the success of healthcare outcomes.”
***I invite you to click on the links below for more detailed information.
***The company plans to introduce video content to its website that will allow for more detailed updates.
Current projects underway include the following:
1. Solutions for Diabetes
Diabetes study currently in a Phase 1 human trial.
Clinicaltrials.gov - Islet Transplantation Using PKX-001.
2. Solutions for blindness from age related macular degeneration
Retinal Cell Replacement study has started Phase 3.
https://www.protokinetix.com/news/2018/august10/
3. Immunology Studies
a) Cord Blood Stem Cell Storage and Recovery.
b) Cord Blood Stem Cell Transplantation and Engraftment.
c) Monoclonal Antibodies, ‘study completed’.
https://www.protokinetix.com/news/2018/january10/
4. Solutions Enabling Healthy Survival of Strokes and Heart Attacks
AAGP® Projects for Cardiac/Heart Research includes:
a) Suppression of doxorubicin toxicity
b) Glucolipotoxity protection
c) Endoplasmic reticulum stress mediation
d) Ischemic damage repair
e) Whole heart ex-vivo preservation
Research being conducted under proprietary MTA agreements include:
5. Solutions enabling increased healthy numbers of life saving stem cells
Material Transfer Agreement ‘A’ includes studies for:
https://www.protokinetix.com/news/2018/june13/
a) Cryopreservation of primary mammalian tissue cells
b) Enhancing the viability of primary mammalian cells
c) Cell lines under stressed culture conditions
6. Material Transfer Agreement ‘B’ includes studies for:
https://www.protokinetix.com/news/2017/june5/
a) Immune Cell Cryopreservation recovery, ‘study completed’
In Our Current Pipeline:
Two studies with an undetermined start dates are Kidney Ischemia and Liver Perfusion.
The company is actively negotiating material transfer agreements with other companies for collaborative research studies.
CEO Clarence Smith notes that the company has adequate cash on hand for project continuation and company operations for the near term.
ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care SolutionsPress Release | 09/04/2018
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix"
(OTCQB KTX) ...President and Chief Executive Officer Clarence Smith is pleased at the progress of the health care applications projects the Company has underway. According to Mr. Smith “To that end, ProtoKinetix is continuing to collaborate with some of the most prestigious research institutions.
..The Company is focusing on research efforts in areas where our AAGP® molecule can significantly impact the success of healthcare outcomes.”
***I invite you to click on the links below for more detailed information.
***The company plans to introduce video content to its website that will allow for more detailed updates.
Current projects underway include the following:
1. Solutions for Diabetes
Diabetes study currently in a Phase 1 human trial.
Clinicaltrials.gov - Islet Transplantation Using PKX-001.
2. Solutions for blindness from age related macular degeneration
Retinal Cell Replacement study has started Phase 3.
https://www.protokinetix.com/news/2018/august10/
3. Immunology Studies
a) Cord Blood Stem Cell Storage and Recovery.
b) Cord Blood Stem Cell Transplantation and Engraftment.
c) Monoclonal Antibodies, ‘study completed’.
https://www.protokinetix.com/news/2018/january10/
4. Solutions Enabling Healthy Survival of Strokes and Heart Attacks
AAGP® Projects for Cardiac/Heart Research includes:
a) Suppression of doxorubicin toxicity
b) Glucolipotoxity protection
c) Endoplasmic reticulum stress mediation
d) Ischemic damage repair
e) Whole heart ex-vivo preservation
Research being conducted under proprietary MTA agreements include:
5. Solutions enabling increased healthy numbers of life saving stem cells
Material Transfer Agreement ‘A’ includes studies for:
https://www.protokinetix.com/news/2018/june13/
a) Cryopreservation of primary mammalian tissue cells
b) Enhancing the viability of primary mammalian cells
c) Cell lines under stressed culture conditions
6. Material Transfer Agreement ‘B’ includes studies for:
https://www.protokinetix.com/news/2017/june5/
a) Immune Cell Cryopreservation recovery, ‘study completed’
In Our Current Pipeline:
Two studies with an undetermined start dates are Kidney Ischemia and Liver Perfusion.
The company is actively negotiating material transfer agreements with other companies for collaborative research studies.
CEO Clarence Smith notes that the company has adequate cash on hand for project continuation and company operations for the near term.
(0)
(0)ProtoKinetix, Inc. (PKTX) Stock Research Links
Scroll down for more posts ▼